Showing results (61-70 of 104) with videos related to
Sort By:
Pageof 11
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.Plos Pathogens|October 13, 2017
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptorRachel S Leibman, Max W Richardson, Christoph T Ellebrecht, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.Cancer Immunology Research|July 22, 2018
Reducing <i>Ex Vivo</i> Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T CellsSaba Ghassemi, Selene Nunez-Cruz, Roddy S O'Connor, et al.Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic LeukemiaNoelle V Frey, Saar Gill, Elizabeth O Hexner, et al.Science Translational Medicine|September 4, 2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaDavid L Porter, Wei-Ting Hwang, Noelle V Frey, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|August 18, 2019
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid CancersAndrew R Haas, Janos L Tanyi, Mark H O'Hara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.Pageof 11